Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data In Beta-Thalassemia To Be Presented At 2013 American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in five abstracts for sotatercept and ACE-536, Acceleron’s programs to treat red blood cell disorders, will be presented at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place on December 7-10 th at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Key information to be presented include new interim data from the ongoing phase 2 clinical trial of sotatercept in patients with beta-thalassemia. Initial interim data from the 0.5 mg/kg dose level will be presented in a poster presentation by the first author Maria-Domenica Cappellini, M.D., University of Milan, Milan, Italy on Monday December 9 th from 6:00 – 8:00 PM CST in Hall E of the convention center. Acceleron has previously provided interim clinical data from the 0.1 mg/kg and 0.3 mg/kg dose levels in this trial.

Additionally, preclinical data from both the sotatercept and ACE-536 programs will be presented at the meeting. Both sotatercept and ACE-536 are being jointly developed through a global collaboration with Celgene Corporation. The presentations from Acceleron, Celgene and academic collaborators will take place as follows:

Sotatercept Clinical Data

Abstract title: “A Phase 2a, Open-Label, Dose-Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults with Beta (β)-Thalassemia: Interim Results”Abstract number: 3448Session: 112. Thalassemia and Globin Gene Regulation: Poster IIIDate: Monday, December 9, 2013Time: 6:00 PM – 8:00 PM CST (Ernest N. Morial Convention Center, Hall E)

Sotatercept Preclinical Data

Abstract title: “Sotatercept Promotes Differentiation and Survival of Erythroid Progenitors by Blocking Inhibitory Effects of TGFβ Superfamily Members”Abstract number: 944Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism and Survival, Excluding Iron: Poster IDate: Saturday, December 7, 2013Time: 5:30 PM – 7:30 PM CST (Ernest N. Morial Convention Center, Hall E)

If you liked this article you might like

Biotech Movers: Acceleron, Clovis, Coherus

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Acceleron Pharma Price Target Raised by Leerink

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting